Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Celexa Approved In Canada For Treatment Of Depression MONTREAL, QC -- Feb. 10, 1999 -- Lundbeck Canada Inc.’s Celexa(R) (citalopram), the most selective serotonin reuptake inhibitor (SSRI), has been approved by Health Canada's Health Protection Branch, for the symptomatic relief of depression. Already a leading SSRI in seven European countries where other SSRIs are also available, Celexa has been proven effective and well tolerated in clinical trials involving over 23,000 patients. "One of Celexa's strengths is that it is well-tolerated by patients," said Dr. Brian Bexton, psychiatrist and psychoanalyst with the Clinique des maladies affectives, Hôpital Sacré-Coeur de Montréal. "For the treatment of depression to be successful, it's important for a medication to be well-tolerated so that the patient can stay on it long enough to get better." Results of Celexa's benefits and antidepressant effects have been demonstrated in several large, placebo-controlled clinical trials, as well as in a number of clinical studies comparing Celexa with tricyclic antidepressants (TCAs) and other SSRIs. These studies have shown that treatment with Celexa consistently and significantly improves symptoms of depression. "Studies have also shown that Celexa has minimal potential for interacting with other commonly prescribed medications," Dr. Bexton said. "This is important in treating older patients with depression who may be taking medications for other illnesses such as cardiovascular disease." Untreated depression in older patients can have serious consequences. The suicide rate in depressed people is twice that of the general population and depression increases the risk of developing heart disease. Though depression is gaining better understanding and acceptance in the community as a whole, older people are often uncomfortable talking about their emotional problems. Some specialists believe that symptoms of depression in older patients may present differently from depression in younger patients. As a consequence, later life mental illness is significantly under diagnosed and under treated. Unfortunately depression is a chronic, recurrent illness and when antidepressants are withdrawn soon after a response, up to 50 per cent of patients will relapse in the following four to six months after drug therapy. A study published in the journal International Clinical Psychopharmacology demonstrated that Celexa is effective in relapse prevention over a period of six months. Celexa is the most recent of the group of antidepressants called SSRIs to be introduced in Canada. SSRIs help increase the amount of serotonin in the brain by interfering with the reuptake of serotonin, a neurotransmitter associated with mood control. Available in over 60 countries world-wide, Celexa has been used to treat an estimated eight million patients with depression. Side effects reported for Celexa were generally mild and went away with treatment. Those reported most often were nausea, dry mouth and sleepiness. Recommended dosage is 20 mg once-daily and, unlike other antidepressants which must be taken with meals, Celexa can be taken any time of the day without regard to food intake. Clinical depression is a biologically-based illness affecting an estimated 20 to 25 per cent Canadians at some point in their life. A serious social problem, it is estimated that depression costs Canada's health care system approximately $6 billion CDN per year in direct and indirect costs. E-mail this page to a friend or colleague! To print, use this version